on the advancement of the drug development enterprise. Among these initiatives is the Cures Acceleration Network (CAN), which was originally authorized in the Patient Protection and Affordable Care Act (P.L. 111-148) and was subsequently amended by the Consolidated Appropriations Act, FY 2012 (P.L. 112-74), which moved CAN to the newly authorized National Center for Advancing Translational Sciences (NCATS).

This public workshop will consider options and opportunities to maximize the usefulness and impact of the CAN program in order to advance translational sciences. In addition to providing suggestions to NCATS, the workshop is, in part, in response to congressional interest in CAN expressed in the FY 2012 appropriations act conference report. The workshop will inform NIH/NCATS in its efforts to implement CAN and advance translational sciences, and will also inform the public, policy community, and other stakeholders as all of these parties continue to work to enhance the development and testing of therapies and diagnostics to patients. The summary will be provided to NCATS and the newly established CAN Board to help it identify ways to accelerate and expand the number of cures.

The workshop objectives are to:

  • Identify and catalog potential tools, methods, and approaches that hold promise for accelerating translational science.

    — Consideration of such promising approaches will draw from the experiences of existing activities at other federal agencies related to the goals of CAN (e.g., FDA, CDC, AHRQ).

  • Discuss the authorities conferred to CAN and identify strategies for effectively using those authorities.

    — Consideration of the CAN authorities will specifically explore the flexible research, or “other transactions,” authority and will reference existing efforts in which such authority is currently applied across other federal agencies (e.g., DARPA, DTRA, BARDA).

  • Explore promising models for public—private collaborations that could be strengthened or facilitated by activities under CAN.

    — Discuss barriers to such collaborations and identify opportunities and potential solutions for moving past the identified barriers.

    — Discuss the respective roles of multiple sectors, including, e.g., biopharma, biotech, venture capital/private equity, and patient/disease advocacy.

  • Identify barriers and potential solutions to facilitate coordination of activities under CAN with the FDA regulatory review process and timelines.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement